- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
According to our latest study, the global Vasomotor Symptoms Treatment market size was valued at USD 9065 million in 2022 and is forecast to a readjusted size of USD 12570 million by 2029 with a CAGR of 4.8% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Vasomotor Symptoms Treatment market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Vasomotor Symptoms Treatment market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Vasomotor Symptoms Treatment market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Vasomotor Symptoms Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Vasomotor Symptoms Treatment market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Vasomotor Symptoms Treatment
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Vasomotor Symptoms Treatment market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer AG, Fervent Pharmaceuticals, LLC, Astellas Pharma Inc., Frazier Healthcare Partners and Mitsubishi Tanabe Pharma Corporation, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Vasomotor Symptoms Treatment market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Hormonal Therapies
Non-Hormonal Therapies
Others
Market segment by Application
Clinic
Hospital
Others
Major players covered
Bayer AG
Fervent Pharmaceuticals, LLC
Astellas Pharma Inc.
Frazier Healthcare Partners
Mitsubishi Tanabe Pharma Corporation
Eli Lilly and Company
AbbVie Inc.
AMAG Pharmaceuticals Inc.
Emcure Pharmaceuticals Limited
Merck & Co., Inc.
Novartis AG
Novo Nordisk A/S
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Vasomotor Symptoms Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Vasomotor Symptoms Treatment, with price, sales, revenue and global market share of Vasomotor Symptoms Treatment from 2018 to 2023.
Chapter 3, the Vasomotor Symptoms Treatment competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Vasomotor Symptoms Treatment breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Vasomotor Symptoms Treatment market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Vasomotor Symptoms Treatment.
Chapter 14 and 15, to describe Vasomotor Symptoms Treatment sales channel, distributors, customers, research findings and conclusion.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Vasomotor Symptoms Treatment
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Vasomotor Symptoms Treatment Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Hormonal Therapies
1.3.3 Non-Hormonal Therapies
1.3.4 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global Vasomotor Symptoms Treatment Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Clinic
1.4.3 Hospital
1.4.4 Others
1.5 Global Vasomotor Symptoms Treatment Market Size & Forecast
1.5.1 Global Vasomotor Symptoms Treatment Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Vasomotor Symptoms Treatment Sales Quantity (2018-2029)
1.5.3 Global Vasomotor Symptoms Treatment Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Bayer AG
2.1.1 Bayer AG Details
2.1.2 Bayer AG Major Business
2.1.3 Bayer AG Vasomotor Symptoms Treatment Product and Services
2.1.4 Bayer AG Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Bayer AG Recent Developments/Updates
2.2 Fervent Pharmaceuticals, LLC
2.2.1 Fervent Pharmaceuticals, LLC Details
2.2.2 Fervent Pharmaceuticals, LLC Major Business
2.2.3 Fervent Pharmaceuticals, LLC Vasomotor Symptoms Treatment Product and Services
2.2.4 Fervent Pharmaceuticals, LLC Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Fervent Pharmaceuticals, LLC Recent Developments/Updates
2.3 Astellas Pharma Inc.
2.3.1 Astellas Pharma Inc. Details
2.3.2 Astellas Pharma Inc. Major Business
2.3.3 Astellas Pharma Inc. Vasomotor Symptoms Treatment Product and Services
2.3.4 Astellas Pharma Inc. Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Astellas Pharma Inc. Recent Developments/Updates
2.4 Frazier Healthcare Partners
2.4.1 Frazier Healthcare Partners Details
2.4.2 Frazier Healthcare Partners Major Business
2.4.3 Frazier Healthcare Partners Vasomotor Symptoms Treatment Product and Services
2.4.4 Frazier Healthcare Partners Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Frazier Healthcare Partners Recent Developments/Updates
2.5 Mitsubishi Tanabe Pharma Corporation
2.5.1 Mitsubishi Tanabe Pharma Corporation Details
2.5.2 Mitsubishi Tanabe Pharma Corporation Major Business
2.5.3 Mitsubishi Tanabe Pharma Corporation Vasomotor Symptoms Treatment Product and Services
2.5.4 Mitsubishi Tanabe Pharma Corporation Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Mitsubishi Tanabe Pharma Corporation Recent Developments/Updates
2.6 Eli Lilly and Company
2.6.1 Eli Lilly and Company Details
2.6.2 Eli Lilly and Company Major Business
2.6.3 Eli Lilly and Company Vasomotor Symptoms Treatment Product and Services
2.6.4 Eli Lilly and Company Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Eli Lilly and Company Recent Developments/Updates
2.7 AbbVie Inc.
2.7.1 AbbVie Inc. Details
2.7.2 AbbVie Inc. Major Business
2.7.3 AbbVie Inc. Vasomotor Symptoms Treatment Product and Services
2.7.4 AbbVie Inc. Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 AbbVie Inc. Recent Developments/Updates
2.8 AMAG Pharmaceuticals Inc.
2.8.1 AMAG Pharmaceuticals Inc. Details
2.8.2 AMAG Pharmaceuticals Inc. Major Business
2.8.3 AMAG Pharmaceuticals Inc. Vasomotor Symptoms Treatment Product and Services
2.8.4 AMAG Pharmaceuticals Inc. Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 AMAG Pharmaceuticals Inc. Recent Developments/Updates
2.9 Emcure Pharmaceuticals Limited
2.9.1 Emcure Pharmaceuticals Limited Details
2.9.2 Emcure Pharmaceuticals Limited Major Business
2.9.3 Emcure Pharmaceuticals Limited Vasomotor Symptoms Treatment Product and Services
2.9.4 Emcure Pharmaceuticals Limited Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Emcure Pharmaceuticals Limited Recent Developments/Updates
2.10 Merck & Co., Inc.
2.10.1 Merck & Co., Inc. Details
2.10.2 Merck & Co., Inc. Major Business
2.10.3 Merck & Co., Inc. Vasomotor Symptoms Treatment Product and Services
2.10.4 Merck & Co., Inc. Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Merck & Co., Inc. Recent Developments/Updates
2.11 Novartis AG
2.11.1 Novartis AG Details
2.11.2 Novartis AG Major Business
2.11.3 Novartis AG Vasomotor Symptoms Treatment Product and Services
2.11.4 Novartis AG Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Novartis AG Recent Developments/Updates
2.12 Novo Nordisk A/S
2.12.1 Novo Nordisk A/S Details
2.12.2 Novo Nordisk A/S Major Business
2.12.3 Novo Nordisk A/S Vasomotor Symptoms Treatment Product and Services
2.12.4 Novo Nordisk A/S Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Novo Nordisk A/S Recent Developments/Updates
2.13 Pfizer Inc.
2.13.1 Pfizer Inc. Details
2.13.2 Pfizer Inc. Major Business
2.13.3 Pfizer Inc. Vasomotor Symptoms Treatment Product and Services
2.13.4 Pfizer Inc. Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Pfizer Inc. Recent Developments/Updates
2.14 Teva Pharmaceutical Industries Ltd.
2.14.1 Teva Pharmaceutical Industries Ltd. Details
2.14.2 Teva Pharmaceutical Industries Ltd. Major Business
2.14.3 Teva Pharmaceutical Industries Ltd. Vasomotor Symptoms Treatment Product and Services
2.14.4 Teva Pharmaceutical Industries Ltd. Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
3 Competitive Environment: Vasomotor Symptoms Treatment by Manufacturer
3.1 Global Vasomotor Symptoms Treatment Sales Quantity by Manufacturer (2018-2023)
3.2 Global Vasomotor Symptoms Treatment Revenue by Manufacturer (2018-2023)
3.3 Global Vasomotor Symptoms Treatment Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Vasomotor Symptoms Treatment by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Vasomotor Symptoms Treatment Manufacturer Market Share in 2022
3.4.2 Top 6 Vasomotor Symptoms Treatment Manufacturer Market Share in 2022
3.5 Vasomotor Symptoms Treatment Market: Overall Company Footprint Analysis
3.5.1 Vasomotor Symptoms Treatment Market: Region Footprint
3.5.2 Vasomotor Symptoms Treatment Market: Company Product Type Footprint
3.5.3 Vasomotor Symptoms Treatment Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Vasomotor Symptoms Treatment Market Size by Region
4.1.1 Global Vasomotor Symptoms Treatment Sales Quantity by Region (2018-2029)
4.1.2 Global Vasomotor Symptoms Treatment Consumption Value by Region (2018-2029)
4.1.3 Global Vasomotor Symptoms Treatment Average Price by Region (2018-2029)
4.2 North America Vasomotor Symptoms Treatment Consumption Value (2018-2029)
4.3 Europe Vasomotor Symptoms Treatment Consumption Value (2018-2029)
4.4 Asia-Pacific Vasomotor Symptoms Treatment Consumption Value (2018-2029)
4.5 South America Vasomotor Symptoms Treatment Consumption Value (2018-2029)
4.6 Middle East and Africa Vasomotor Symptoms Treatment Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2029)
5.2 Global Vasomotor Symptoms Treatment Consumption Value by Type (2018-2029)
5.3 Global Vasomotor Symptoms Treatment Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2029)
6.2 Global Vasomotor Symptoms Treatment Consumption Value by Application (2018-2029)
6.3 Global Vasomotor Symptoms Treatment Average Price by Application (2018-2029)
7 North America
7.1 North America Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2029)
7.2 North America Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2029)
7.3 North America Vasomotor Symptoms Treatment Market Size by Country
7.3.1 North America Vasomotor Symptoms Treatment Sales Quantity by Country (2018-2029)
7.3.2 North America Vasomotor Symptoms Treatment Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2029)
8.2 Europe Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2029)
8.3 Europe Vasomotor Symptoms Treatment Market Size by Country
8.3.1 Europe Vasomotor Symptoms Treatment Sales Quantity by Country (2018-2029)
8.3.2 Europe Vasomotor Symptoms Treatment Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Vasomotor Symptoms Treatment Market Size by Region
9.3.1 Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Vasomotor Symptoms Treatment Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2029)
10.2 South America Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2029)
10.3 South America Vasomotor Symptoms Treatment Market Size by Country
10.3.1 South America Vasomotor Symptoms Treatment Sales Quantity by Country (2018-2029)
10.3.2 South America Vasomotor Symptoms Treatment Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Vasomotor Symptoms Treatment Market Size by Country
11.3.1 Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Vasomotor Symptoms Treatment Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Vasomotor Symptoms Treatment Market Drivers
12.2 Vasomotor Symptoms Treatment Market Restraints
12.3 Vasomotor Symptoms Treatment Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Vasomotor Symptoms Treatment and Key Manufacturers
13.2 Manufacturing Costs Percentage of Vasomotor Symptoms Treatment
13.3 Vasomotor Symptoms Treatment Production Process
13.4 Vasomotor Symptoms Treatment Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Vasomotor Symptoms Treatment Typical Distributors
14.3 Vasomotor Symptoms Treatment Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
List of Tables
Table 1. Global Vasomotor Symptoms Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Vasomotor Symptoms Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Bayer AG Basic Information, Manufacturing Base and Competitors
Table 4. Bayer AG Major Business
Table 5. Bayer AG Vasomotor Symptoms Treatment Product and Services
Table 6. Bayer AG Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Bayer AG Recent Developments/Updates
Table 8. Fervent Pharmaceuticals, LLC Basic Information, Manufacturing Base and Competitors
Table 9. Fervent Pharmaceuticals, LLC Major Business
Table 10. Fervent Pharmaceuticals, LLC Vasomotor Symptoms Treatment Product and Services
Table 11. Fervent Pharmaceuticals, LLC Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Fervent Pharmaceuticals, LLC Recent Developments/Updates
Table 13. Astellas Pharma Inc. Basic Information, Manufacturing Base and Competitors
Table 14. Astellas Pharma Inc. Major Business
Table 15. Astellas Pharma Inc. Vasomotor Symptoms Treatment Product and Services
Table 16. Astellas Pharma Inc. Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Astellas Pharma Inc. Recent Developments/Updates
Table 18. Frazier Healthcare Partners Basic Information, Manufacturing Base and Competitors
Table 19. Frazier Healthcare Partners Major Business
Table 20. Frazier Healthcare Partners Vasomotor Symptoms Treatment Product and Services
Table 21. Frazier Healthcare Partners Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Frazier Healthcare Partners Recent Developments/Updates
Table 23. Mitsubishi Tanabe Pharma Corporation Basic Information, Manufacturing Base and Competitors
Table 24. Mitsubishi Tanabe Pharma Corporation Major Business
Table 25. Mitsubishi Tanabe Pharma Corporation Vasomotor Symptoms Treatment Product and Services
Table 26. Mitsubishi Tanabe Pharma Corporation Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Mitsubishi Tanabe Pharma Corporation Recent Developments/Updates
Table 28. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 29. Eli Lilly and Company Major Business
Table 30. Eli Lilly and Company Vasomotor Symptoms Treatment Product and Services
Table 31. Eli Lilly and Company Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Eli Lilly and Company Recent Developments/Updates
Table 33. AbbVie Inc. Basic Information, Manufacturing Base and Competitors
Table 34. AbbVie Inc. Major Business
Table 35. AbbVie Inc. Vasomotor Symptoms Treatment Product and Services
Table 36. AbbVie Inc. Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. AbbVie Inc. Recent Developments/Updates
Table 38. AMAG Pharmaceuticals Inc. Basic Information, Manufacturing Base and Competitors
Table 39. AMAG Pharmaceuticals Inc. Major Business
Table 40. AMAG Pharmaceuticals Inc. Vasomotor Symptoms Treatment Product and Services
Table 41. AMAG Pharmaceuticals Inc. Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. AMAG Pharmaceuticals Inc. Recent Developments/Updates
Table 43. Emcure Pharmaceuticals Limited Basic Information, Manufacturing Base and Competitors
Table 44. Emcure Pharmaceuticals Limited Major Business
Table 45. Emcure Pharmaceuticals Limited Vasomotor Symptoms Treatment Product and Services
Table 46. Emcure Pharmaceuticals Limited Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Emcure Pharmaceuticals Limited Recent Developments/Updates
Table 48. Merck & Co., Inc. Basic Information, Manufacturing Base and Competitors
Table 49. Merck & Co., Inc. Major Business
Table 50. Merck & Co., Inc. Vasomotor Symptoms Treatment Product and Services
Table 51. Merck & Co., Inc. Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Merck & Co., Inc. Recent Developments/Updates
Table 53. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 54. Novartis AG Major Business
Table 55. Novartis AG Vasomotor Symptoms Treatment Product and Services
Table 56. Novartis AG Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Novartis AG Recent Developments/Updates
Table 58. Novo Nordisk A/S Basic Information, Manufacturing Base and Competitors
Table 59. Novo Nordisk A/S Major Business
Table 60. Novo Nordisk A/S Vasomotor Symptoms Treatment Product and Services
Table 61. Novo Nordisk A/S Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Novo Nordisk A/S Recent Developments/Updates
Table 63. Pfizer Inc. Basic Information, Manufacturing Base and Competitors
Table 64. Pfizer Inc. Major Business
Table 65. Pfizer Inc. Vasomotor Symptoms Treatment Product and Services
Table 66. Pfizer Inc. Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Pfizer Inc. Recent Developments/Updates
Table 68. Teva Pharmaceutical Industries Ltd. Basic Information, Manufacturing Base and Competitors
Table 69. Teva Pharmaceutical Industries Ltd. Major Business
Table 70. Teva Pharmaceutical Industries Ltd. Vasomotor Symptoms Treatment Product and Services
Table 71. Teva Pharmaceutical Industries Ltd. Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
Table 73. Global Vasomotor Symptoms Treatment Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 74. Global Vasomotor Symptoms Treatment Revenue by Manufacturer (2018-2023) & (USD Million)
Table 75. Global Vasomotor Symptoms Treatment Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 76. Market Position of Manufacturers in Vasomotor Symptoms Treatment, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 77. Head Office and Vasomotor Symptoms Treatment Production Site of Key Manufacturer
Table 78. Vasomotor Symptoms Treatment Market: Company Product Type Footprint
Table 79. Vasomotor Symptoms Treatment Market: Company Product Application Footprint
Table 80. Vasomotor Symptoms Treatment New Market Entrants and Barriers to Market Entry
Table 81. Vasomotor Symptoms Treatment Mergers, Acquisition, Agreements, and Collaborations
Table 82. Global Vasomotor Symptoms Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 83. Global Vasomotor Symptoms Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 84. Global Vasomotor Symptoms Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 85. Global Vasomotor Symptoms Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 86. Global Vasomotor Symptoms Treatment Average Price by Region (2018-2023) & (US$/Unit)
Table 87. Global Vasomotor Symptoms Treatment Average Price by Region (2024-2029) & (US$/Unit)
Table 88. Global Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 89. Global Vasomotor Symptoms Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 90. Global Vasomotor Symptoms Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 91. Global Vasomotor Symptoms Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 92. Global Vasomotor Symptoms Treatment Average Price by Type (2018-2023) & (US$/Unit)
Table 93. Global Vasomotor Symptoms Treatment Average Price by Type (2024-2029) & (US$/Unit)
Table 94. Global Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 95. Global Vasomotor Symptoms Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 96. Global Vasomotor Symptoms Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 97. Global Vasomotor Symptoms Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 98. Global Vasomotor Symptoms Treatment Average Price by Application (2018-2023) & (US$/Unit)
Table 99. Global Vasomotor Symptoms Treatment Average Price by Application (2024-2029) & (US$/Unit)
Table 100. North America Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 101. North America Vasomotor Symptoms Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 102. North America Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 103. North America Vasomotor Symptoms Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 104. North America Vasomotor Symptoms Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 105. North America Vasomotor Symptoms Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 106. North America Vasomotor Symptoms Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 107. North America Vasomotor Symptoms Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 108. Europe Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 109. Europe Vasomotor Symptoms Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 110. Europe Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 111. Europe Vasomotor Symptoms Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 112. Europe Vasomotor Symptoms Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 113. Europe Vasomotor Symptoms Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 114. Europe Vasomotor Symptoms Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 115. Europe Vasomotor Symptoms Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 116. Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 117. Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 118. Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 119. Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 120. Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 121. Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 122. Asia-Pacific Vasomotor Symptoms Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 123. Asia-Pacific Vasomotor Symptoms Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 124. South America Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 125. South America Vasomotor Symptoms Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 126. South America Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 127. South America Vasomotor Symptoms Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 128. South America Vasomotor Symptoms Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 129. South America Vasomotor Symptoms Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 130. South America Vasomotor Symptoms Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 131. South America Vasomotor Symptoms Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 132. Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 133. Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 134. Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 135. Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 136. Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 137. Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 138. Middle East & Africa Vasomotor Symptoms Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 139. Middle East & Africa Vasomotor Symptoms Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 140. Vasomotor Symptoms Treatment Raw Material
Table 141. Key Manufacturers of Vasomotor Symptoms Treatment Raw Materials
Table 142. Vasomotor Symptoms Treatment Typical Distributors
Table 143. Vasomotor Symptoms Treatment Typical Customers
List of Figures
Figure 1. Vasomotor Symptoms Treatment Picture
Figure 2. Global Vasomotor Symptoms Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Vasomotor Symptoms Treatment Consumption Value Market Share by Type in 2022
Figure 4. Hormonal Therapies Examples
Figure 5. Non-Hormonal Therapies Examples
Figure 6. Others Examples
Figure 7. Global Vasomotor Symptoms Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Vasomotor Symptoms Treatment Consumption Value Market Share by Application in 2022
Figure 9. Clinic Examples
Figure 10. Hospital Examples
Figure 11. Others Examples
Figure 12. Global Vasomotor Symptoms Treatment Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Vasomotor Symptoms Treatment Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Vasomotor Symptoms Treatment Sales Quantity (2018-2029) & (K Units)
Figure 15. Global Vasomotor Symptoms Treatment Average Price (2018-2029) & (US$/Unit)
Figure 16. Global Vasomotor Symptoms Treatment Sales Quantity Market Share by Manufacturer in 2022
Figure 17. Global Vasomotor Symptoms Treatment Consumption Value Market Share by Manufacturer in 2022
Figure 18. Producer Shipments of Vasomotor Symptoms Treatment by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 19. Top 3 Vasomotor Symptoms Treatment Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Top 6 Vasomotor Symptoms Treatment Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Global Vasomotor Symptoms Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 22. Global Vasomotor Symptoms Treatment Consumption Value Market Share by Region (2018-2029)
Figure 23. North America Vasomotor Symptoms Treatment Consumption Value (2018-2029) & (USD Million)
Figure 24. Europe Vasomotor Symptoms Treatment Consumption Value (2018-2029) & (USD Million)
Figure 25. Asia-Pacific Vasomotor Symptoms Treatment Consumption Value (2018-2029) & (USD Million)
Figure 26. South America Vasomotor Symptoms Treatment Consumption Value (2018-2029) & (USD Million)
Figure 27. Middle East & Africa Vasomotor Symptoms Treatment Consumption Value (2018-2029) & (USD Million)
Figure 28. Global Vasomotor Symptoms Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 29. Global Vasomotor Symptoms Treatment Consumption Value Market Share by Type (2018-2029)
Figure 30. Global Vasomotor Symptoms Treatment Average Price by Type (2018-2029) & (US$/Unit)
Figure 31. Global Vasomotor Symptoms Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 32. Global Vasomotor Symptoms Treatment Consumption Value Market Share by Application (2018-2029)
Figure 33. Global Vasomotor Symptoms Treatment Average Price by Application (2018-2029) & (US$/Unit)
Figure 34. North America Vasomotor Symptoms Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 35. North America Vasomotor Symptoms Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 36. North America Vasomotor Symptoms Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 37. North America Vasomotor Symptoms Treatment Consumption Value Market Share by Country (2018-2029)
Figure 38. United States Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Canada Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Mexico Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Europe Vasomotor Symptoms Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 42. Europe Vasomotor Symptoms Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 43. Europe Vasomotor Symptoms Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 44. Europe Vasomotor Symptoms Treatment Consumption Value Market Share by Country (2018-2029)
Figure 45. Germany Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. France Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. United Kingdom Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Russia Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Italy Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 51. Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 52. Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 53. Asia-Pacific Vasomotor Symptoms Treatment Consumption Value Market Share by Region (2018-2029)
Figure 54. China Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Japan Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Korea Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. India Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Southeast Asia Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Australia Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. South America Vasomotor Symptoms Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 61. South America Vasomotor Symptoms Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 62. South America Vasomotor Symptoms Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 63. South America Vasomotor Symptoms Treatment Consumption Value Market Share by Country (2018-2029)
Figure 64. Brazil Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Argentina Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 67. Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 68. Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 69. Middle East & Africa Vasomotor Symptoms Treatment Consumption Value Market Share by Region (2018-2029)
Figure 70. Turkey Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Egypt Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Saudi Arabia Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. South Africa Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Vasomotor Symptoms Treatment Market Drivers
Figure 75. Vasomotor Symptoms Treatment Market Restraints
Figure 76. Vasomotor Symptoms Treatment Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Vasomotor Symptoms Treatment in 2022
Figure 79. Manufacturing Process Analysis of Vasomotor Symptoms Treatment
Figure 80. Vasomotor Symptoms Treatment Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
